Meeting
2014 Gastrointestinal Cancers Symposium
Effectiveness study of gemcitabine, oxaliplatin, and capecitabine as first-line treatment for nonresectable biliary tract cancer.
Authors
Lars Henrik Jensen
Danish Colorectal Cancer Group South, Vejle Hospital and University of Southern Denmark, Vejle, Denmark
Lars Henrik Jensen , Anne Haahr Mellergaard , Dan Hoegdall , Ole Larsen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 334)
DOI
10.1200/jco.2014.32.3_suppl.334
Abstract #
334
Poster Bd #
C49
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
First Author: Vaibhav Sahai
Poster
2021 ASCO Annual Meeting
A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).
First Author: Choong-kun Lee
Poster
2021 Gastrointestinal Cancers Symposium
Efficacy and safety of 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) for previously treated advanced pancreatic cancer (APC).
First Author: Hiromichi Shirasu
Poster
2019 ASCO Annual Meeting
Nab-paclitaxel plus S-1 as first line treatment for advanced or metastatic biliary tract adenocarcinoma: A phase 2 study.
First Author: Yongkun Sun